A novel biomarker is in development to find patients that might benefit from the medication Actos (used in diabetes) in the treatment of Alzheimers.  Follow the links to read about a license agreement that will lead to a study for using this medication in Alzheimers.  It appears Actos may interfere with brain inflammation and amyloid build up in the brain.
 
 http://www.medcitynews.com/2011/01/alzheimers-testing-technology-licensed-to-takeda-in-87-million-deal/
 
http://www.healthsystem.virginia.edu/internet/news/archives06/diabetes_drug.cfm